SyB-0702
Alternative Names: PEG-ZnPP; SyB 0702Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Sojo University
- Developer SymBio Pharmaceuticals
- Class
- Mechanism of Action Heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Japan (Parenteral)
- 27 Jun 2011 Preclinical development in Solid tumours is ongoing in Japan
- 27 Jun 2011 SyB-0702 is available for licensing as of 27 Jun 2011. http://www.symbiopharma.com